How to translate pharmacokinetic data into dosing recommendations

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10319899" target="_blank" >RIV/00216208:11110/15:10319899 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10319899

Výsledek na webu

<a href="http://dx.doi.org/10.1159/000364989" target="_blank" >http://dx.doi.org/10.1159/000364989</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1159/000364989" target="_blank" >10.1159/000364989</a>

Jazyk výsledku

angličtina

Název v původním jazyce

How to translate pharmacokinetic data into dosing recommendations

Popis výsledku v původním jazyce

Pharmacotherapy in children is challenging due to limited knowledge of the influence of physiological changes on drug exposure and response. Differences in drug pharmacokinetics are often considered the main drivers of age-related differences in dose requirements in neonates and young infants. Pharmacokinetic parameters in these young children can be derived from a 'population analysis' of drug concentration measurements in the blood at various time points after drug administration. A major advantage ofperforming a population analysis is that it allows investigations into betweensubject variability. Patient characteristics that can describe patterns in the variability of pharmacokinetic parameters can be used to predict these pharmacokinetic parameters in other patients within the same population. The distribution volume of a drug is the main driver of peak concentrations, whereas drug clearance is the driver of steady state concentrations. Information on how these parameters differ b

Název v anglickém jazyce

How to translate pharmacokinetic data into dosing recommendations

Popis výsledku anglicky

Pharmacotherapy in children is challenging due to limited knowledge of the influence of physiological changes on drug exposure and response. Differences in drug pharmacokinetics are often considered the main drivers of age-related differences in dose requirements in neonates and young infants. Pharmacokinetic parameters in these young children can be derived from a 'population analysis' of drug concentration measurements in the blood at various time points after drug administration. A major advantage ofperforming a population analysis is that it allows investigations into betweensubject variability. Patient characteristics that can describe patterns in the variability of pharmacokinetic parameters can be used to predict these pharmacokinetic parameters in other patients within the same population. The distribution volume of a drug is the main driver of peak concentrations, whereas drug clearance is the driver of steady state concentrations. Information on how these parameters differ b

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FG - Pediatrie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pediatric and Adolescent Medicine

ISSN

1017-5989

e-ISSN

—

Svazek periodika

18

Číslo periodika v rámci svazku

-

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

15

Strana od-do

13-27

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-84914680357